In 2020, for the first time we provided evidence about the importance of CD137+ T-cells in determining the outcome of metastatic non-small cells lung cancer (NSCLC) patients undergoing immunotherapies [67,68]. This evidence concerns the gene TNFRSF9 and non-small cell lung carcinoma.